630 RIBAVIRIN (RBV) DOSAGE AS INDEPENDENT PREDICTOR OF RVR IN HCV GENOTYPE 2 (HCV-2) AND 3 (HCV-3) PATIENTS UNDERGOING COMBINED TREATMENT WITH PEG INTERFERON (PEG-IFN) ALPHA-2B

A. Mangia1, O. Dalgard2, N. Minerva3, H. Verbaan4, G. Scotto5, D. Bacca6, E. Agostinacchio7, K. Bjoro8, V. Carretta9, V. Piazzolla1, R. Cozzolongo10, M. Romano11, L. Mottola1, A. Andriulli12. 1Liver Unit, IRCCS ‘Casa Sollievo della Sofferenza’, San Giovanni Rotondo, Italy; 2Medical Department, Aker University Hospital, Oslo, Norway; 3Medical Department, Hospital, Canosa, Italy; 4Department of Surgery, Division of Gastroenterology and Hepatology, University Hospital, Malmoe, Sweden; 5Infectious Diseases Department, University Hospital, Foggia, 6Medical Department, Hospital, Casarano, 7Medical Department, ‘Santa Rita’ Hospital, Bari, Italy; 8Medical Department, RiksHospital, Oslo, Norway; 9Medical Department, Hospital, Venosa, 10Gastroenterology Department, IRCCS ‘S. De Bellis’, Castellana Grotte, 11Medical Department, ‘S. Pertini’ Hospital, Roma, 12Gastroenterology Department, IRCCS ‘Casa Sollievo della Sofferenza’, San Giovanni Rotondo, Italy E-mail: a.mangia@tin.it